Orforglipron + B6 24mg

Oral capsule: Swallow intact with water with or without food. As a small-molecule GLP-1R agonist, orforglipron does not require fasting or restricted fluid volume for adequate absorption. Administer at the same time each day for consistent plasma exposure. Do not crush or split the capsule unless specifically directed by the prescriber or pharmacist.

Dosing is prescriber-determined. The 24 mg strength is intended for patients who have tolerated lower doses (e.g., 12 mg or earlier titration steps) per their individualized escalation schedule.

• Titration context: GLP-1R agonist therapy requires dose escalation over weeks to months to optimize tolerability; 24 mg represents a higher-tier maintenance dose step.
• Pyridoxine (B6): Dose is prescriber-specified, co-administered to mitigate nausea.
• Final dose, titration schedule, and treatment duration are determined solely by the prescriber based on efficacy, tolerability, and clinical goals.

• Orforglipron: Full agonist at the GLP-1 receptor (class B GPCR); stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon, delays gastric emptying, and activates hypothalamic and brainstem satiety centers. As a small molecule, it is orally bioavailable without DPP-4 degradation concerns and achieves receptor occupancy comparable to injectable peptide analogues at appropriate doses.
• Pyridoxine (B6): Vitamin B6 functions as an essential cofactor in amino acid and neurotransmitter metabolism; its antiemetic mechanism likely involves modulation of central serotonergic pathways. Clinical data support pyridoxine as an antiemetic in pregnancy-related nausea and it is used adjunctively here to reduce GLP-1R agonist-induced GI adverse effects.

Indications context: The 24 mg compounded orforglipron + B6 capsule is intended for adult patients with obesity or overweight with comorbidities, or type 2 diabetes, who are progressing through a prescriber-directed titration and have demonstrated tolerability at lower doses. Prescribers should confirm that the patient's clinical status supports dose escalation prior to advancing to 24 mg.

Prescriber monitoring considerations:

• Reassess weight, glycemic parameters (HbA1c, fasting glucose), and GI tolerability at each dose escalation step.
• Monitor renal function — GI fluid losses can precipitate acute kidney injury, especially in the elderly.
• Evaluate for pancreatitis symptoms at each visit (persistent severe abdominal pain, elevated lipase).
• Monitor for thyroid nodules or symptoms in patients with relevant risk history.
• Review concomitant medications — delayed gastric emptying affects oral drug absorption kinetics for narrow therapeutic index drugs.

Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Known hypersensitivity to orforglipron or any component of the formulation

Warnings & Precautions:

• Thyroid C-cell tumors: rodent carcinogenicity signal across GLP-1R agonist class; human relevance not established
• Acute pancreatitis: suspend use and evaluate if suspected
• Acute gallbladder disease: evaluate biliary symptoms promptly
• GI side effects: nausea, vomiting, diarrhea are most common at dose escalation; may cause dehydration and AKI
• Gastroparesis: avoid or use with caution in patients with pre-existing delayed gastric emptying

Drug Interactions:

• Insulin and sulfonylureas: heightened hypoglycemia risk; dose reduction of secretagogue may be required
• Narrow therapeutic index oral drugs: monitor for altered absorption due to delayed gastric emptying
• Oral contraceptives: monitor for potential changes in absorption timing

Common Side Effects: Nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, eructation, and fatigue. Higher doses are associated with greater frequency of GI adverse events.

Store at controlled room temperature (20–25°C / 68–77°F), protected from light and moisture, in the original dispensing container. Do not refrigerate or freeze unless the label specifies. The beyond-use date assigned by Genesis Compounding appears on the label. Keep out of reach of children and discard after the beyond-use date.

Why did my prescriber increase my dose to 24 mg?

Orforglipron titration follows a stepped schedule designed to minimize GI side effects while progressing toward an effective therapeutic dose. The 24 mg dose represents an advanced titration step, indicating you have tolerated earlier lower doses and your prescriber has determined escalation is appropriate for your clinical goals.

Will nausea get worse at 24 mg?

GI side effects are most common during the first 1–4 weeks after each dose increase. Pyridoxine (B6) is included in this formulation to help reduce nausea. Symptoms typically improve as the body adapts to the higher dose. Report persistent or severe vomiting to your prescriber.

Do I need to fast before taking this?

No special fasting requirement exists for orforglipron as a small-molecule oral agent. It may be taken with or without food, unlike some other oral GLP-1 formulations. Consistency of daily timing is recommended.

Can I take this long-term?

GLP-1R agonists are intended for chronic use in the management of obesity and type 2 diabetes. Long-term continuation, dose adjustments, and monitoring are guided by your prescriber based on ongoing clinical assessment.

Is this FDA-approved?

Orforglipron was FDA-approved in April 2026. This compounded 24 mg + B6 capsule is a prescriber-directed, patient-specific 503A preparation by Genesis Compounding and is not FDA-approved as a compounded product.